Inozyme Pharma Inc (INZY)
Stock chart
Earnings
Value bought
Past 90 days
Value sold
Past 90 days
Net insiders buying
Past 90 days
Trades (buy and sell)
Past 90 days
Search
| Notification date | Transaction date | B/S Transaction type | Insider and/or position |
Nb. shares Price Value |
Number of shares | Price | Value | Details |
|---|---|---|---|---|---|---|---|---|
| 2025-04-03 | 2025-04-02 | S Sale |
CEO & Chairman Executive Director |
8,819
-17.7%
0.89USD 7,849 |
8,819 -17.7% | 0.89 | USD 7,849 | |
| 2024-04-03 | 2024-04-02 | S Sale |
CEO Executive Director |
7,523
-26.7%
6.94USD 52,210 |
7,523 -26.7% | 6.94 | USD 52,210 | |
| 2023-08-03 | 2023-08-01 | B Purchase | Non-Executive Director |
714,285
+83.3%
4.80USD 3,428,568 |
714,285 +83.3% | 4.80 | USD 3,428,568 | |
| 2023-08-03 | 2023-08-01 | B Purchase | Non-Executive Director |
119,048
+4.2%
4.80USD 571,430 |
119,048 +4.2% | 4.80 | USD 571,430 | |
| 2023-08-03 | 2023-08-01 | B Purchase |
Pivotal bioVenture Partners Fund I, L.P. Non-Executive Director |
714,285
+83.3%
4.80USD 3,428,568 |
714,285 +83.3% | 4.80 | USD 3,428,568 | |
| 2023-08-03 | 2023-08-01 | B Purchase |
Pivotal bioVenture Partners Fund I, L.P. Non-Executive Director |
119,048
+4.2%
4.80USD 571,430 |
119,048 +4.2% | 4.80 | USD 571,430 | |
| 2023-05-15 | 2023-05-12 | B Purchase | Non-Executive Director |
228,702
+6.7%
6.25USD 1,429,388 |
228,702 +6.7% | 6.25 | USD 1,429,388 | |
| 2023-05-15 | 2023-05-11 | B Purchase | Non-Executive Director |
219,230
+6.8%
6.48USD 1,420,610 |
219,230 +6.8% | 6.48 | USD 1,420,610 | |
| 2023-03-30 | 2023-03-29 | B Purchase | Non-Executive Director |
344,592
+12.0%
4.54USD 1,563,724 |
344,592 +12.0% | 4.54 | USD 1,563,724 | |
| 2023-03-29 | 2023-03-28 | B Purchase | Non-Executive Director |
156,766
+5.8%
4.16USD 652,335 |
156,766 +5.8% | 4.16 | USD 652,335 | |
| 2023-03-29 | 2023-03-27 | B Purchase | Non-Executive Director |
51,074
+1.9%
3.70USD 188,729 |
51,074 +1.9% | 3.70 | USD 188,729 | |
| 2022-12-19 | 2022-12-15 | B Purchase |
SVP, COO Officer |
21,500
+25.6%
1.39USD 29,885 |
21,500 +25.6% | 1.39 | USD 29,885 | |
| 2022-04-21 | 2022-04-19 | B Purchase |
Longitude Capital Partners III, LLC Large shareholder |
1,355,000
+48.1%
3.69USD 4,999,950 |
1,355,000 +48.1% | 3.69 | USD 4,999,950 | |
| 2022-04-20 | 2022-04-19 | B Purchase |
Chief Executive Officer Executive Director |
67,750
+35.5%
3.69USD 249,998 |
67,750 +35.5% | 3.69 | USD 249,998 | |
| 2022-04-20 | 2022-04-19 | B Purchase |
SVP, CFO Officer |
27,100
+inf%
3.69USD 99,999 |
27,100 +inf% | 3.69 | USD 99,999 | |
| 2022-04-20 | 2022-04-19 | B Purchase |
Pivotal bioVenture Partners Fund I, L.P. Non-Executive Director |
1,070,000
+67.2%
3.69USD 3,948,300 |
1,070,000 +67.2% | 3.69 | USD 3,948,300 | |
| 2022-04-20 | 2022-04-19 | B Purchase | Non-Executive Director |
1,070,000
+67.2%
3.69USD 3,948,300 |
1,070,000 +67.2% | 3.69 | USD 3,948,300 | |
| 2022-04-20 | 2022-04-19 | B Purchase |
SVP, COO Officer |
27,100
+50.6%
3.69USD 99,999 |
27,100 +50.6% | 3.69 | USD 99,999 | |
| 2021-06-25 | 2021-06-24 | S Sale |
Chief Executive Officer Executive Director |
66,788
-25.9%
0.00USD 7 |
66,788 -25.9% | 0.00 | USD 7 | |
| 2021-02-01 | 2021-01-28 | S Sale | Large shareholder |
375,000
-14.6%
21.00USD 7,875,000 |
375,000 -14.6% | 21.00 | USD 7,875,000 |